Deepak JaisankarDirector, Advisory
Deepak Jaisankar is a Director in Perella Weinberg Partners’ Advisory business. He primarily focuses on advising clients in the healthcare sector.
Mr. Jaisankar has more than 8 years of investment banking experience assisting companies on a wide range of strategic matters. Selected transaction experience includes advising HealthEquity, Inc. on its acquisition of WageWorks, Inc. for $2 billion, AMAG Pharmaceuticals, Inc. on its carve-out and sale of Cord Blood Registry to GI Partners for $530 million, Sagent Pharmaceuticals, Inc. on its sale to Nichi-Iko Pharmaceutical Co., Ltd. For $736 million, Perella Weinberg Partners on its combination with Tudor, Pickering, Holt & Co., and Medtronic, Inc. on its acquisition of Covidien plc for $49 billion, among others.
Prior to joining Perella Weinberg Partners in July of 2015, Mr. Jaisankar was at the International Finance Corporation from 2010 to 2013, where he most recently served as an Investment Analyst responsible for renewable energy and infrastructure investments across emerging markets. He was previously at DnB Markets in Singapore, where he provided M&A and capital markets advice to clients in the oil & gas and shipping sectors in South East Asia and the Middle East.
Mr. Jaisankar earned a Bachelor of Science with a double major in Economics and Finance from Singapore Management University and a Master of Business Administration from The Wharton School at the University of Pennsylvania.